ANA+ (anti-nuclear antibody) is correlated with RF+ (rheumatoid factor) in rheumatoid arthritis

Author： Matsos Mark P.  

Publisher： VSP

ISSN： 1568-5608

Source： Inflammopharmacology, Vol.12, Iss.3, 2004-01, pp. : 229-231

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-TNF Treatment in Rheumatoid Arthritis

By  

Current Pharmaceutical Design, Vol. 17, Iss. 29, 2011-10 ,pp. : 3141-3151

Bentham Science Publishers

Access to resources Recommend Favorite

According to The British Society for Rheumatology guidelines, 5.6% of outpatients with rheumatoid arthritis (RA) in the West Midlands, UK, are eligible for anti-tumour necrosis factor (TNF) monoclonal antibody therapy

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 422, 2003-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis

By Coenen Marieke JH   Toonen Erik JM   Scheffer Hans   Radstake Timothy RDJ   Barrera Pilar   Franke Barbara  

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 761-773

Future Medicine

Access to resources Recommend Favorite

Anti-cytokines and Cytokines in the Treatment of Rheumatoid Arthritis

By  

Current Pharmaceutical Design, Vol. 9, Iss. 14, 2003-01 ,pp. : 1095-1126

Bentham Science Publishers

Access to resources Recommend Favorite

Tumour necrosis factor blockade in rheumatoid arthritis

By Breedveld Ferdinand C  

Clinical Medicine, Vol. 1, Iss. 2, 2001-03 ,pp. : 107-109

Royal College Of Physicians

Access to resources Recommend Favorite